Moleculin Biotech, Inc. announced a private placement to issue 14,089,672 shares of common stock the Common Warrants at an issue price of $0.64 per share for the gross proceeds of 9,017,390.08 on December 20, 2023. The transaction will include participation from Walter V. Klemp, Jonathan P. Foster and certain other employees and advisors, and a member of the Company?s board of directors purchased an aggregate of up to 652,172 Common Warrants in the Private Placement on the same terms as the other investors participating in the Offering. The closing of the Private Placement is subject to customary closing conditions and is expected to occur on December 26, 2023.

The Common Warrants to be issued in the Private Placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the ?Securities Act?), and Regulation D promulgated thereunder and have not been registered under the Securities Act or applicable state securities laws.